EA201070063A1 - Комбинации sap-истощающих агентов и анти-sap антител - Google Patents

Комбинации sap-истощающих агентов и анти-sap антител

Info

Publication number
EA201070063A1
EA201070063A1 EA201070063A EA201070063A EA201070063A1 EA 201070063 A1 EA201070063 A1 EA 201070063A1 EA 201070063 A EA201070063 A EA 201070063A EA 201070063 A EA201070063 A EA 201070063A EA 201070063 A1 EA201070063 A1 EA 201070063A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sap
combinations
antibodies
explosive agents
explosive
Prior art date
Application number
EA201070063A
Other languages
English (en)
Other versions
EA026959B1 (ru
Inventor
Марк Брайан Пепис
Original Assignee
Пентрексин Терапьютикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пентрексин Терапьютикс Лимитед filed Critical Пентрексин Терапьютикс Лимитед
Publication of EA201070063A1 publication Critical patent/EA201070063A1/ru
Publication of EA026959B1 publication Critical patent/EA026959B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение описывает применение соединения, которое устраняет сывороточный амилоидный Р-компонент из циркуляции, в комбинации с антителом, специфичным в отношении сывороточного амилоидного Р-компонента, для лечения или профилактики амилоидоза.
EA201070063A 2007-06-27 2008-06-27 Набор, содержащий агент, устраняющий sap, и анти-sap антитело, и способ лечения или профилактики амилоидной болезни EA026959B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0712503.2A GB0712503D0 (en) 2007-06-27 2007-06-27 Use
PCT/EP2008/058333 WO2009000926A1 (en) 2007-06-27 2008-06-27 Combinations of sap depleting agents and anti-sap antibodies

Publications (2)

Publication Number Publication Date
EA201070063A1 true EA201070063A1 (ru) 2010-06-30
EA026959B1 EA026959B1 (ru) 2017-06-30

Family

ID=38420831

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070063A EA026959B1 (ru) 2007-06-27 2008-06-27 Набор, содержащий агент, устраняющий sap, и анти-sap антитело, и способ лечения или профилактики амилоидной болезни

Country Status (14)

Country Link
US (2) US7910106B2 (ru)
EP (1) EP2173341B1 (ru)
JP (1) JP5695903B2 (ru)
KR (1) KR101605448B1 (ru)
CN (1) CN101801372B (ru)
AU (1) AU2008267148B2 (ru)
BR (1) BRPI0813655A2 (ru)
CA (2) CA2691054C (ru)
DK (1) DK2173341T3 (ru)
EA (1) EA026959B1 (ru)
ES (2) ES2582389T3 (ru)
GB (1) GB0712503D0 (ru)
MX (1) MX342991B (ru)
WO (1) WO2009000926A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008358292B2 (en) * 2008-06-27 2015-05-07 Pentraxin Therapeutics Limited Use
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
US9434716B2 (en) 2011-03-01 2016-09-06 Glaxo Group Limited Antigen binding proteins
KR101365980B1 (ko) * 2011-06-24 2014-02-24 한양대학교 산학협력단 리튬 공기 전지
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
US9737505B2 (en) * 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
GB201407506D0 (en) 2014-04-29 2014-06-11 Glaxosmithkline Ip Dev Ltd Novel compound
CN105254734A (zh) * 2015-07-16 2016-01-20 中国科学院海洋研究所 一种鱼类血清淀粉样p成分及其应用
WO2017072090A1 (en) * 2015-10-27 2017-05-04 Glaxosmithkline Intellectual Property Development Limited Combination therapy
CA3065149A1 (en) * 2017-05-31 2018-12-06 Kyowa Kirin Co., Ltd. Nucleic acid suppressing expression of apcs
EP3714054A1 (en) 2017-11-20 2020-09-30 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
WO2020128816A2 (en) 2018-12-20 2020-06-25 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
IL302388A (en) * 2020-11-02 2023-06-01 Attralus Inc SAP FC fusion proteins and methods of use
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
PT915088E (pt) * 1997-10-31 2003-01-31 Hoffmann La Roche Derivados de d-prolina
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
JP4707231B2 (ja) * 1998-06-10 2011-06-22 スタテンズ セーラム インスティテュート マンナン結合レクチンを製造するための精製方法及びｍｂｌ医薬品
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2004059318A2 (en) * 2002-12-23 2004-07-15 William Marsh Rice University Methods of detecting the inhibition of fibrocyte formation and methods and compositions for enhancing fibrocyte formation
CA2525302A1 (en) * 2003-05-12 2004-11-18 David Bundle Multivalent inhibitors of serum amyloid p component

Also Published As

Publication number Publication date
MX2009013840A (es) 2013-07-29
US20110166329A1 (en) 2011-07-07
GB0712503D0 (en) 2007-08-08
BRPI0813655A2 (pt) 2014-12-30
DK2173341T3 (en) 2016-07-25
AU2008267148A1 (en) 2008-12-31
JP5695903B2 (ja) 2015-04-08
CA2691054A1 (en) 2008-12-31
CA2691054C (en) 2017-11-14
EP2173341A1 (en) 2010-04-14
AU2008267148B2 (en) 2014-06-12
KR20100050495A (ko) 2010-05-13
MX342991B (es) 2016-10-20
CN101801372B (zh) 2014-11-26
US9192668B2 (en) 2015-11-24
ES2729648T3 (es) 2019-11-05
EA026959B1 (ru) 2017-06-30
CA2729034A1 (en) 2009-12-30
US7910106B2 (en) 2011-03-22
EP2173341B1 (en) 2016-06-08
WO2009000926A1 (en) 2008-12-31
US20090191196A1 (en) 2009-07-30
JP2010531338A (ja) 2010-09-24
CN101801372A (zh) 2010-08-11
CA2729034C (en) 2018-10-30
KR101605448B1 (ko) 2016-03-22
ES2582389T3 (es) 2016-09-12

Similar Documents

Publication Publication Date Title
EA201070063A1 (ru) Комбинации sap-истощающих агентов и анти-sap антител
TW200603828A (en) Treatment of disorders
ECSP088529A (es) Anticuerpos anti mn y métodos para su utilización
DK3312197T3 (da) Monoklonale antistoffer mod claudin-18 til behandling af cancer
CY2016029I2 (el) Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτιλισινης κεχιν τυπου 9(pcsk9)
CY2016030I2 (el) Αντισωματα εναντι της il-17
CY2016038I1 (el) Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1
NL1032452A1 (nl) Menselijke monoklonale antilichamen tegen activine receptor-achtig kinase-1.
ATE521365T1 (de) Kinin-antagonisten zur behandlung von blasenfunktionsstörung
DK2135881T3 (da) Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
BRPI0816919A2 (pt) Redução de infecções concomitantes em porcos pelo uso de antígeno pcv2.
CU20120095A7 (es) Antagonistas de pcsk9
MX355268B (es) Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos.
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
EP1921137A4 (en) ANTIBODIES WITH INHIBITOR EFFECT ON THE FORMATION OF AMYLOID FIBRILLES
EA201000888A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов
EA200900767A1 (ru) Антагонистические антитела против ephb3
BRPI0818865A2 (pt) Anticorpos monoclonais contra proteína c ativada.
EA200802072A1 (ru) Ликопин для лечения нарушения обмена веществ
BRPI0815399A2 (pt) tratamento de câncer usando anticorpos humanizados que se ligam ephb4
DE502006007167D1 (de) Gehäuse für eine abgasbehandlungskomponente mit verstärkungshülse
ITRM20040105A1 (it) Anticorpo monoclonale antitenascina umana.
EA202193238A1 (ru) Аффинные агенты к аав9

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU